| Ident. | Authors (with country if any) | Title |
|---|
| 000041 (2013) |
Cem Gabay [Suisse] ; Paul Emery [Royaume-Uni] ; Ronald Van Vollenhoven [Suède] ; Ara Dikranian [États-Unis] ; Rieke Alten [Allemagne] ; Karel Pavelka [République tchèque] ; Micki Klearman [États-Unis] ; David Musselman [États-Unis] ; Sunil Agarwal [États-Unis] ; Jennifer Green [Royaume-Uni] ; Arthur Kavanaugh [États-Unis] | Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial |
| 000050 (2013) |
Mark C. Genovese [États-Unis, Allemagne, Autriche, Canada, Espagne, Royaume-Uni, Suède] ; Andrea Rubbert-Roth ; Josef S. Smolen ; Joel Kremer ; Majed Khraishi ; Juan Gomez-Reino ; Anthony Sebba ; Robert Pilson ; Sarah Williams ; Ronald Van Vollenhoven | Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure |
| 000056 (2013) |
A. Douros [Allemagne] ; E. Bronder [Allemagne] ; F. Andersohn [Allemagne] ; A. Klimpel [Allemagne] ; M. Thomae [Allemagne] ; J. Ockenga [Allemagne] ; R. Kreutz [Allemagne] ; E. Garbe [Allemagne] | Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases |
| 000060 (2013) |
Maxime Dougados [France] ; Karsten Kissel [Suisse] ; Tom Sheeran [Royaume-Uni] ; Paul P. Tak [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martin Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Federico Navarro-Sarabia [Espagne] ; Antony Hou [Pays-Bas] ; Corrado Bernasconi [Suisse] ; Twj Huizinga | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| 000072 (2012) |
Charalampos Dragonas [Allemagne] ; Boris Ehrenstein [Allemagne] ; Martin Fleck [Allemagne] | Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection |
| 000074 (2012) |
Vivian P. Bykerk [États-Unis, Canada] ; Andrew J. K. Östör [Royaume-Uni] ; José Alvaro-Gracia [Espagne] ; Karel Pavelka [République tchèque] ; José Andrés Román Ivorra [Espagne] ; Winfried Graninger [Autriche] ; William Bensen [Canada] ; Michael T. Nurmohamed [Pays-Bas] ; Andreas Krause [Allemagne] ; Corrado Bernasconi [Suisse] ; Andrea Stancati [Suisse] ; Jean Sibilia [France] | Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice |
| 000085 (2012) |
Veronika R. Lang [Allemagne] ; Matthias Englbrecht [Allemagne] ; Jürgen Rech [Allemagne] ; Hubert Nüsslein [Allemagne] ; Karin Manger [Allemagne] ; Florian Schuch [Allemagne] ; Hans-Peter Tony [Allemagne] ; Martin Fleck [Allemagne] ; Bernhard Manger [Allemagne] ; Georg Schett [Allemagne] ; Jochen Zwerina [Allemagne, Australie] | Risk of infections in rheumatoid arthritis patients treated with tocilizumab |
| 000092 (2012) |
Karel Pavelka [République tchèque] ; Arthur F. Kavanaugh [États-Unis] ; Andrea Rubbert-Roth [Allemagne] ; Gianfranco Ferraccioli [Italie] | Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs |
| 000097 (2012) |
Stefan Schanz [Allemagne] ; Marc Schmalzing [Allemagne] ; Emmanuella Guenova [Allemagne] ; Gisela Metzler [Allemagne] ; Anja Ulmer [Allemagne] ; Ina Kötter [Allemagne] ; Gerhard Fierlbeck [Allemagne] | Interstitial Granulomatous Dermatitis With Arthritis Responding to Tocilizumab |
| 000103 (2012) |
Vibeke Strand [États-Unis] ; Gerd R. Burmester [Allemagne] ; Sarika Ogale [États-Unis] ; Jenny Devenport [États-Unis] ; Ani John [États-Unis] ; Paul Emery [Royaume-Uni] | Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study |
| 000105 (2012) |
Morten A. Karsdal [Danemark] ; Georg Schett [Allemagne] ; Paul Emery [Royaume-Uni] ; Olivier Harari [Royaume-Uni] ; Inger Byrjalsen [Danemark] ; Andy Kenwright [Royaume-Uni] ; Anne C. Bay-Jensen [Danemark] ; Adam Platt [Royaume-Uni] | IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522) |
| 000118 (2012) |
Andrea Rubbert-Roth [Allemagne] | Assessing the safety of biologic agents in patients with rheumatoid arthritis |
| 000150 (2011) |
Christof Iking-Konert [Allemagne] ; Martin Aringer [Allemagne] ; Jurgen Wollenhaupt [Allemagne] ; Thomas Mosch [Allemagne] ; Stefan Tuerk [Allemagne] ; Eugen Feist [Allemagne] ; Gerd R. Burmester [Allemagne] | Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria |
| 000160 (2011) |
Petra Roll [Allemagne] ; Khalid Muhammad [Allemagne] ; Mathias Schumann [Allemagne] ; Stefan Kleinert [Allemagne] ; Hermann Einsele [Allemagne] ; Thomas Dörner [Allemagne] ; Hans-Peter Tony [Allemagne] | In Vivo Effects of the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab on the B Cell Compartment |
| 000162 (2011) |
Khalid Muhammad [Allemagne] ; Petra Roll [Allemagne] ; Thomas Seibold [Allemagne] ; Stefan Kleinert [Allemagne] ; Hermann Einsele [Allemagne] ; Thomas Dörner [Allemagne] ; Hans-Peter Tony [Allemagne] | Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells |
| 000167 (2011) |
Gerd R. Burmester [Allemagne] ; E. Feist [Allemagne] ; H. Kellner [Allemagne] ; J. Braun [Allemagne] ; C. Iking-Konert [Allemagne] ; A. Rubbert-Roth [Allemagne] | Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase Illb real-life study (TAMARA) |
| 000177 (2011) |
K. Krüger [Allemagne] | Kombinationsbehandlung von Methotrexat mit DMARDs oder Biologika - Aktueller Stand : Aktueller Stand bei Methotrexat |
| 000197 (2010) |
Kay Stubenrauch [Allemagne] ; Uwe Wessels [Allemagne] ; Herbert Birnboeck [Suisse] ; Francisco Ramirez [Royaume-Uni] ; Angelika Jahreis ; Julia Schleypen [Allemagne] | Subset Analysis of Patients Experiencing Clinical Events of a Potentially Immunogenic Nature in the Pivotal Clinical Trials of Tocilizumab for Rheumatoid Arthritis: Evaluation of an Antidrug Antibody ELISA Using Clinical Adverse Event- Driven Immunogenicity Testing |
| 000203 (2010) |
Joerg C. Henes [Allemagne] ; Marius Horger [Allemagne] ; Ilhan Guenaydin [Allemagne] ; Lothar Kanz [Allemagne] ; Ina Koetter [Allemagne] | Mixed response to tocilizumab for ankylosing spondylitis |
| 000212 (2010) |
P. Roll [Allemagne] ; A. Rubbert-Roth [Allemagne] ; H.-P. Tony [Allemagne] | Tocilizumab: Was kommt nach TNF-Blockern im klinischen Alltag? : Was kommt nach TNF-Blockern im klinischen Alltag ? |
| 000213 (2010) |
J. Wollenhaupt [Allemagne] ; K. Krüger [Allemagne] | Nicht-TNF-Biologika in der Therapiestrategie bei rheumatoider Arthritis : Was kommt nach TNF-Blockern im klinischen Alltag ? |
